People: Novo Nordisk A/S (NVO)
9 Dec 2013
Dr. Thomas (Tom) Paul Koestler, Ph.D. has served as Independent Member of the Board of Directors of Novo Nordisk A/S since March 23, 2011. He is an Executive with Vatera Holdings LLC, the United States. From 2003 to 2009, he was Executive Vice President, and from 2006 President of Schering-Plough Research Institute. Before joining Schering-Plough Research Institute, he was Senior Vice President and Global Head of Regulatory Affairs of Pharmacia Corporation, from 2001. From 1996 to 2001, he was Vice President, later Senior Vice President in Novartis Pharmaceuticals within Regulatory Affairs. From 1982 to 1996, he held various management positions within Regulatory Affairs and Clinical Safety in Sandoz Pharmaceutical Corporation, Johnson & Johnson Bristol-Myers Squibb, and Smith Kline French Labs. He is a Member of the Board of Directors of Momenta Pharmaceuticals Inc., ImmusanT Inc., Arisaph Pharmaceuticals Inc., Rib-X Pharmaceuticals Inc., and Pearl Therapeutics Inc. He is also Chairman of the Scientific Advisory Board of Bausch & Lomb. He has Research and Development knowledge, both generally and within the field of regulatory affairs. He has know-how about the pharmaceutical industry in general and how international corporations operate. He has additional knowledge of the United States market. He holds a Bachelor of Science degree in Biology from Daemen College from 1975, and a Doctorate of Philosophy degree in Medicine and Pathology from the Roswell Park Memorial Institute, part of State University of New York, from 1982.
|Total Annual Compensation, DKK||Long-Term Incentive Plans, DKK||All Other, DKK||Fiscal Year Total, DKK|